Povofortay EU Approval: First Once-Daily Pill for Hidradenitis Suppurativa
The EU approved Incyte's Povofortay (povorcitinib), the first once-daily oral treatment for moderate to severe hidradenitis suppurativa after anti-TNF therapy. Trial data, safety and US timing.
